Pure Global: Brazil's AI Software Gambit - Decoding ANVISA's New Compliance Maze.

Brazil's health regulator, ANVISA, has just shaken up the digital health landscape. A new draft resolution brings critical clarifications for AI-powered medical software, creating a clearer but much stricter pathway to Latin America's largest market. This move could accelerate innovation for some, while creating major new hurdles for others. This episode unpacks the critical details of this regulatory shift. We explore the dilemma facing manufacturers of AI-driven diagnostics: the new rules provide a clearer roadmap for approval but demand an unprecedented level of control and documentation over adaptive algorithms and patient data, potentially stalling the very innovation they seek to foster. Key Takeaways From This Episode: - What are the specific new requirements for managing changes in AI/ML medical software in Brazil? - How does this new resolution interact with Brazil's General Data Protection Law (LGPD)? - Is your current Quality Management System prepared for these new post-market surveillance demands? - What kind of validation data will ANVISA now expect for adaptive algorithms? - How can you turn this regulatory tightening from a barrier into a competitive advantage? - Could Brazil's new AI software framework become the new standard for other LATAM markets? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.